[Orthoclone OKT3 in the treatment of intractable acute renal allograft rejection].
Fifteen patients receiving cadaveric renal allograft had intractable acute rejection during the application cyclosporin-A (Cs-A), from 1991 to 1992. After treating with orthoclone (OKT3, switzerland), 13 patients recovered and 2 died of cerebro-vascular diseases. The main side-effects of OKT3 were sensitization, over-immunosuppression and cytokine release syndrome. The symptoms included chills, fever, dyspnea, diarrhea, pulmonary edema, etc. We consider that when the acute rejection of renal allograft is resistant to Cs-A or steroids, OKT3 is a good therapy with high reverse rate.
Yu
L X
LX
Nanfang Hospital, First Military Medical University, Guangzhou.
D000293:Adolescent; D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*
D016853:Muromonab-CD3; D016572:Cyclosporine